Combination therapy with toripalimab and anlotinib in advanced esophageal squamous cell carcinoma: A case report

被引：0
作者：
Chen, Si-Cong [1 ]
Ma, Dong-Heng [1 ]
Zhong, Jia-Jian [1 ]
机构：
[1] Huazhong Univ Sci & Technol, Union Shenzhen Hosp, Hepatobiliary & Pancreat Surg, 89 Taoyuan Rd, Shenzhen 518052, Guangdong, Peoples R China
来源：
WORLD JOURNAL OF CLINICAL CASES | 2023年 / 11卷 / 27期
关键词：
Esophageal squamous cell carcinoma; Toripalimab; Anlotinib; Complete response; Case report; IMMUNOTHERAPY; CANCER; ANGIOGENESIS; PACLITAXEL;
D O I：
10.12998/wjcc.v11.i27.6579
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BACKGROUNDToripalimab and anlotinib have shown good response in esophageal cancer, with high objective response rate and progression free survival. Thus, they have been approved as second-line or above-line therapy for advanced or unresectable esophageal carcinoma. Combination of these two drugs may have synergistic effects, but evidence of which is lacking.CASE SUMMARYHere, we report on a 73-year-old male, newly diagnosed with advanced esophageal squamous cell carcinoma (ESCC), who received a combination of toripalimab and anlotinib. Complete response was achieved after treatment for 3 mo and remission was maintained up to 14 mo.CONCLUSIONThe combination therapy of toripalimab and anlotinib is a promising treatment for unresectable ESCC and related clinical trials are warranted.
引用
收藏
页码：6579 / 6586
页数：8
相关论文
共 20 条
[1]   Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges [J].
Fukurnura, Dal ;
Kloepper, Jonas ;
Amoozgar, Zohreh ;
Duda, Dan G. ;
Jain, Rakesh K. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (05) :325-340
[2]   Combined targeted therapy and immunotherapy for cancer treatment [J].
Guo, Cheng-Xiang ;
Huang, Xing ;
Xu, Jian ;
Zhang, Xiao-Zhen ;
Shen, Yi-Nan ;
Liang, Ting-Bo ;
Bai, Xue-Li .
WORLD JOURNAL OF CLINICAL CASES, 2021, 9 (26) :7643-7652
[3]   Clinical Activity and Safety of Penpulimab (Anti-PD-1) With Anlotinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: An Open-Label, Multicenter, Phase Ib/II Trial (AK105-203) [J].
Han, Chun ;
Ye, Sisi ;
Hu, Chunhong ;
Shen, Liangfang ;
Qin, Qun ;
Bai, Yuxian ;
Yang, Shizhong ;
Bai, Chunmei ;
Zang, Aimin ;
Jiao, Shunchang ;
Bai, Li .
FRONTIERS IN ONCOLOGY, 2021, 11
[4]   Advances and challenges in the treatment of esophageal cancer [J].
He, Shiming ;
Xu, Jian ;
Liu, Xiujun ;
Zhen, Yongsu .
ACTA PHARMACEUTICA SINICA B, 2021, 11 (11) :3379-3392
[5]   Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma [J].
He, Wenwu ;
Leng, Xuefeng ;
Mao, Tianqin ;
Luo, Xi ;
Zhou, Lingxiao ;
Yan, Jiaxin ;
Peng, Lin ;
Fang, Qiang ;
Liu, Guangyuan ;
Wei, Xing ;
Wang, Kangning ;
Wang, Chenghao ;
Zhang, Sha ;
Zhang, Xudong ;
Shen, Xudong ;
Huang, Depei ;
Yi, Huan ;
Bei, Ting ;
She, Xueke ;
Xiao, Wenguang ;
Han, Yongtao .
ONCOLOGIST, 2022, 27 (01) :E18-E28
[6]   Anlotinib for previously treated advanced or metastatic esophageal squamous cell carcinoma: A double-blind randomized phase 2 trial [J].
Huang, Jing ;
Xiao, Juxiang ;
Fang, Wentao ;
Lu, Ping ;
Fan, Qingxia ;
Shu, Yongqian ;
Feng, Jifeng ;
Zhang, Shu ;
Ba, Yi ;
Zhao, Yang ;
Liu, Ying ;
Bai, Chunmei ;
Bai, Yuxian ;
Tang, Yong ;
Song, Yan ;
He, Jie .
CANCER MEDICINE, 2021, 10 (05) :1681-1689
[7]   Antiangiogenesis Combined with Immunotherapy to Treat Advanced Small-Cell Carcinoma of the Esophagus Resistant to Chemotherapy: According to the Guidance of Next-Generation Sequencing [J].
Jiang, Man ;
Zhang, Xiaochun .
ONCOTARGETS AND THERAPY, 2021, 14 :1613-1621
[8]   Efficacy and safety of anlotinib plus programmed death-1 blockade versus anlotinib monotherapy as second or further-line treatment in advanced esophageal squamous cell carcinoma: A retrospective study [J].
Liu, Ying ;
Ge, Qingqing ;
Xu, Shuning ;
Li, Ke ;
Liu, Ying .
FRONTIERS IN ONCOLOGY, 2022, 12
[9]   Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? [J].
Ramjiawan, Rakesh R. ;
Griffioen, Arjan W. ;
Duda, Dan G. .
ANGIOGENESIS, 2017, 20 (02) :185-204
[10]   Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with EGFR mutations or baseline liver metastases in a randomised, open-label phase 3 trial [J].
Reck, Martin ;
Mok, Tony S. K. ;
Nishio, Makoto ;
Jotte, Robert M. ;
Cappuzzo, Federico ;
Orlandi, Francisco ;
Stroyakovskiy, Daniil ;
Nogami, Naoyuki ;
Rodriguez-Abreu, Delvys ;
Moro-Sibilot, Denis ;
Thomas, Christian A. ;
Barlesi, Fabrice ;
Finley, Gene ;
Lee, Anthony ;
Coleman, Shelley ;
Deng, Yu ;
Kowanetz, Marcin ;
Shankar, Geetha ;
Lin, Wei ;
Socinski, Mark A. .
LANCET RESPIRATORY MEDICINE, 2019, 7 (05) :387-401
12